Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss.

[1]  A. Schmidt,et al.  Receptor for advanced glycation end products, inflammation, and accelerated periodontal disease in diabetes: mechanisms and insights into therapeutic modalities. , 2001, Annals of periodontology.

[2]  T. Miyata,et al.  Possible involvement of advanced glycation end-products in bone resorption. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  L. Kuller,et al.  Bone Mineral Density and Blood Flow to the Lower Extremities: The Study of Osteoporotic Fractures , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  A. Blumsohn.  Bone remodeling markers: Assessment of fracture risk and fracture risk reduction , 2003, Current osteoporosis reports.

[5]  M. Willheim,et al.  Differential stimulation by PGE(2) and calcemic hormones of IL-6 in stromal/osteoblastic cells. , 2000, Biochemical and biophysical research communications.

[6]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[7]  Loredana Cornero,et al.  Women , 1893, The Hospital.

[8]  P. Secchiero,et al.  TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. , 2004, Blood.

[9]  D. Hogge,et al.  The effects of interleukin 6 and interleukin 3 on early hematopoietic events in long-term cultures of human marrow. , 1991, Experimental hematology.

[10]  K. Herold,et al.  Receptor for Advanced Glycation End Products , 2008, Annals of the New York Academy of Sciences.

[11]  A. Schmidt,et al.  RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease , 2002, Cellular and Molecular Life Sciences CMLS.

[12]  A. Schwartz,et al.  Women, type 2 diabetes, and fracture risk , 2004, Current diabetes reports.

[13]  Y. Seino,et al.  Diabetic osteopenia: pathophysiology and clinical aspects. , 1995, Diabetes/metabolism reviews.

[14]  T. Kishimoto,et al.  Advanced Glycation Endproducts Stimulate Interleukin‐6 Production by Human Bone‐Derived Cells , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  D. Graves,et al.  A role for advanced glycation end products in diminished bone healing in type 1 diabetes. , 2003, Diabetes.

[16]  N. Kugai,et al.  Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  T. Kishimoto,et al.  The biology of interleukin-6. , 1989, Blood.

[18]  T. Kislinger,et al.  Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. , 2000, The Journal of clinical investigation.

[19]  Allan Bradley,et al.  Increased bone formation in osteocalcin-deficient mice , 1996, Nature.

[20]  Paul J Thornalley.  Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. , 1998, Cellular and molecular biology.

[21]  Y. Zou,et al.  Receptor for Advanced-Glycation End Products: Key Modulator of Myocardial Ischemic Injury , 2006, Circulation.

[22]  E. Schleicher,et al.  Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. , 1997, The Journal of clinical investigation.

[23]  D. Rao,et al.  Bone Loss and Bone Turnover in Diabetes , 1995, Diabetes.

[24]  V. D’Agati,et al.  Receptor for Advanced Glycation End Products Mediates Inflammation and Enhanced Expression of Tissue Factor in Vasculature of Diabetic Apolipoprotein E–Null Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[25]  E. Ravussin,et al.  Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus. , 1995, The Journal of clinical endocrinology and metabolism.

[26]  L. Avioli,et al.  Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. , 1976, The New England journal of medicine.

[27]  Rainer Constien,et al.  Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line , 2001, Genesis.

[28]  I. Reid,et al.  Abnormal cell calcium concentrations in cultured bone cells obtained from femurs of obese and noninsulin-dependent diabetic rats , 1989, Calcified Tissue International.

[29]  J. Clausen,et al.  The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. , 1998, Diabetes care.

[30]  J. Schneider,et al.  Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. , 2004, The Journal of clinical investigation.

[31]  R. Abs,et al.  Bone Mass and Bone Density in Maturity-type Diabetics Measured by the 125I Photon-absorption Technique , 1977, Diabetes.

[32]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.